Medscape4d
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications
The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...
The American Journal of Managed Care3d
Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
Managed Healthcare Executive7d
Patient Experience With Intravenous and Subcutaneous Therapies
An expert gastroenterologist dissects a study that analyzed patient experience with intravenous and subcutaneous biological therapies.
Targeted Oncology10d
Data Shows Subcutaneous Rituximab Similar to IV in Non-Hodgkin Lymphoma
Subcutaneous and intravenous forms of rituximab showed similar efficacy in patients with non-Hodgkin lymphoma.
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and ...
Cure Today7d
FDA Approves Subcutaneous Tecentriq Formulation
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin ...
Managed Healthcare Executive4d
FDA Approves Subcutaneous Ocrevus for Multiple Sclerosis
Ocrevus Zunovo can be administrated by providers twice a year with a 10-minute subcutaneous injection. Ocrevus Zunovo will be ...
Multiple Sclerosis News Today4d
Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...
Medscape6d
FDA Okays Subcutaneous Ocrelizumab for MS
Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...
FiercePharma6d
Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...